Working… Menu

A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00854152
Recruitment Status : Completed
First Posted : March 3, 2009
Last Update Posted : November 2, 2016
Information provided by (Responsible Party):
Genentech, Inc.

Brief Summary:
This is an open-label, multicenter, Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of GDC-0980 administered to patients with incurable, locally advanced or metastatic solid malignancy or NHL that has progressed or failed to respond to at least one prior regimen or for which there is no standard therapy.

Condition or disease Intervention/treatment Phase
Non-Hodgkin's Lymphoma, Solid Cancers Drug: GDC-0980 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 121 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Phase I, Dose-Escalation Study Evaluating the Safety, Tolerability, and Maximally Tolerated Dose of GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors and Non-Hodgkin's Lymphoma
Study Start Date : March 2009
Actual Primary Completion Date : November 2014
Actual Study Completion Date : November 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: 1 Drug: GDC-0980
Escalating repeating dose

Primary Outcome Measures :
  1. Occurrence of adverse events [ Time Frame: Length of study ]
  2. Occurrence of dose-limiting toxicities [ Time Frame: Length of study ]
  3. PK parameters after doses of GDC-0980 [ Time Frame: Length of study ]
  4. Occurrence of Grade 3 and 4 abnormalities in safety-related laboratory parameters and associated dose of GDC-0980 [ Time Frame: Length of study ]

Secondary Outcome Measures :
  1. Best overall response, duration of objective response, and progression-free survival for patients with measurable disease [ Time Frame: Length of study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically documented, incurable, locally advanced or metastatic solid malignancies, or NHL without leukemic phase, that has progressed despite standard of care therapy or for which there is no standard therapy of proven clinical benefit
  • ECOG performance status of 0 or 1 at screening
  • Evaluable or measurable disease per RECIST and/or the following: prostate cancer patients with non-measurable disease are eligible if they have two rising prostate-specific antigen (PSA) levels that meet the PSA Working Group criteria for progression prior to initiation of study treatment; ovarian cancer patients with non-measurable disease are eligible if they have two rising CA-125 levels greater than the ULN >= 2 weeks apart prior to initiation of study treatment.
  • Life expectancy >=12 weeks
  • Adequate hematologic and organ function within 14 days before initiation of GDC-0980
  • Documented willingness to use an effective means of contraception for both men and women while participating in the study

Exclusion Criteria:

  • Leptomeningeal disease as the only manifestation of the current malignancy
  • History of Type 1 or 2 diabetes mellitus requiring regular medication
  • Grade >= 2 hypercholesterolemia or hypertriglyceridemia
  • Ejection fraction that is <50% or below the LLN (whichever is higher), as determined by echocardiogram or MUGA scan
  • DLCO < 50% of predicted value corrected for hemoglobin and alveolar volume prior to initiation of GDC-0980
  • Malabsorption syndrome or other condition that would interfere with enteral absorption
  • Known untreated malignancies of the brain or spinal cord, or treated brain metastases that are not radiographically stable for >= 3 months
  • Active congestive heart failure or ventricular arrhythmia requiring medication
  • Active infection requiring IV antibiotics
  • Requirement for any daily supplemental oxygen
  • Uncontrolled hypomagnesemia
  • Hypercalcemia requiring continued use of bisphosphonate therapy
  • Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
  • Uncontrolled ascites requiring frequent paracentesis
  • Known HIV infection
  • Any other diseases, active or controlled pulmonary dysfunction, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug
  • Significant traumatic injury within 4 weeks of Day 1
  • Major surgical procedure within 4 weeks prior to initiation of GDC-0980
  • For all patients participating in Stage 2: Prior treatment with any PI3K inhibitor, mTOR inhibitor or dual PI3K/mTOR inhibitor. For HNSCC patients, this restriction applies only to any PI3K inhibitor, mTOR inhibitor, or dual PI3K/mTOR inhibitor used in the palliative setting.
  • Treatment with chemotherapy, hormonal therapy (except hormone replacement therapy, oral contraceptives, or GnRH agonists or antagonists for prostate cancer), immunotherapy, biologic therapy, radiation therapy (except palliative radiation to bony metastases), or herbal therapy as cancer therapy within 3 weeks prior to initiation of GDC-0980
  • Palliative radiation to bony metastases within 2 weeks prior to initiation of GDC-0980
  • Need for chronic corticosteroid therapy of >= 10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids or immunosuppressant
  • Treatment with an investigational agent within 4 weeks prior to initiation of GDC-0980
  • Unresolved toxicity from prior therapy except for alopecia and Grade 1 peripheral neuropathy
  • Pregnancy or lactation
  • For patients participating in DCE-MRI assessments, any contraindication to MRI examination
  • For patients with advanced solid tumors or NHL participating in the PPI-effect assessment: Known hypersensitivity to rabeprazole, substituted benzimidazoles, or to any component of the formulation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00854152

Layout table for location information
United States, Illinois
Chicago, Illinois, United States, 60637
United States, Massachusetts
Boston, Massachusetts, United States, 02115
United States, New York
New York, New York, United States, 10065
United States, Tennessee
Nashville, Tennessee, United States, 37203
United Kingdom
Sutton, United Kingdom, SM2 5PT
Sponsors and Collaborators
Genentech, Inc.
Layout table for investigator information
Study Director: Mika Derynck, M.D. Genentech, Inc.
Layout table for additonal information
Responsible Party: Genentech, Inc. Identifier: NCT00854152    
Other Study ID Numbers: PIM4604g
MP00880 ( Other Identifier: Hoffmann-La Roche )
First Posted: March 3, 2009    Key Record Dates
Last Update Posted: November 2, 2016
Last Verified: November 2016
Keywords provided by Genentech, Inc.:
Carcinogenic Tumors
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases